Regulatory News:
POXEL SA (Euronext: POXEL FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2024.
Event | Date* |
2023 Annual Results | October 3, 2024 |
2024 Third Quarter Financial Update | November 6, 2024 |
Annual General Meeting | November 28, 2024 |
2024 First Half Results | December 9, 2024 |
* Subject to modification.
All corporate information on Poxel, including financial statements, press releases and corporate presentations, is available on the Investors page of the Company's website.
Annual General Meeting
In accordance with its bylaws, the financial year of Poxel ended on December 31, 2023. By order of July 3, 2024, the President of the Lyon Commercial Court, with whom the request had been filed, extended the deadline for the Annual General Meeting to December 31, 2024.
The Company informs its shareholders that the Annual General Meeting called to approve the corporate and consolidated financial statements for the year ended December 31, 2023, will be held on November 28, 2024.
About Poxel SA
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.
For more information, please visit: www.poxelpharma.com
All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241001622428/en/
Contacts:
Investor relations Media
NewCap
Nicolas Fossiez, Aurélie Manavarere Arthur Rouillé
poxel@newcap.eu
+33 1 44 71 94 94
